FLAGSTAFF, Arizona, Oct. 2, 2019 /PRNewswire/ -- W. L. Gore & Associates [https://c212.net/c/link/?t=0&l=en&o=2592708-1&h=2828932744&u=https%3A%2F%2Fwww.goremedical.com%2Feu&a=W.+L.+Gore+%26+Associates] (Gore) has introduced the newest member of its family of occluders, the GORE® CARDIOFORM ASD Occluder [https://c212.net/c/link/?t=0&l=en&o=2592708-1&h=994204152&u=https%3A%2F%2Fwww.goremedical.com%2Feu%2Fproducts%2Fcardioform%2Fasd-occluder&a=GORE%C2%AE+CARDIOFORM+ASD+Occluder], which has received CE Mark. The device offers physicians a clinically proven design in a device that, in a recent study, met its primary endpoint for the percutaneous, transcatheter closure of ostium secundum atrial defects (ASDs).
Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8615951-gore-cardioform-asd-occluder-receives-ce-mark/ [https://c212.net/c/link/?t=0&l=en&o=2592708-1&h=3765201627&u=https%3A%2F%2Fwww.multivu.com%2Fplayers%2FEnglish%2F8615951-gore-cardioform-asd-occluder-receives-ce-mark%2F&a=https%3A%2F%2Fwww.multivu.com%2Fplayers%2FEnglish%2F8615951-gore-cardioform-asd-occluder-receives-ce-mark%2F]
The Gore ASSURED Clinical Study demonstrated safety, closure, and technical success that statistically achieved the primary endpoint. The new addition to the Gore portfolio extends what physicians can achieve with the GORE CARDIOFORM Occluder family.
The GORE CARDIOFORM ASD Occluder's anatomically adaptable waist conforms to the defect to close ASDs from 8mm to 35mm in diameter, including those without a retro-aortic rim, by facilitating optimal tissue ingrowth, while maintaining thromboresistance. The ability to retrieve and reposition the GORE CARDIOFORM ASD Occluder helps ensure proper positioning and offers physicians confident closure.
"Larger defects typically have a greater risk for complications, like pulmonary hypertension, right heart enlargement, or atrial fibrillation. But previously, Europe didn't have access to the GORE CARDIOFORM ASD Occluder for this range of defects," said Matthew Gillespie, M.D., Children's Hospital of Philadelphia, co-principal investigator of the ASSURED Clinical Study. "CE Mark makes this soft, conformable device available for the minimally invasive treatment of a broader range of ASDs."
The pivotal study evaluated the safety and efficacy of ASD closure using the GORE CARDIOFORM ASD Occluder in 125 patients with evidence of right heart volume overload demonstrating the need for defect closure. The study involved patients between the ages of 2 and 84, across 22 investigation sites, including 15 children's hospitals. The pivotal study met its safety, closure, and technical success primary endpoints.
"Leading interventional cardiologists worldwide informed its development, and its design builds on decades of clinical experience and manufacturing excellence."
"As the latest extension of the GORE CARDIOFORM Occluder family, the GORE CARDIOFORM ASD Occluder builds on a legacy of safety," said Jake Goble, M.B.A, Ph.D., Gore Structural Heart Pipeline Leader. "Leading interventional cardiologists worldwide informed its development, and its design builds on decades of clinical experience and manufacturing excellence."
The GORE CARDIOFORM ASD Occluder was recently granted approval by the U.S. Food and Drug Administration [https://c212.net/c/link/?t=0&l=en&o=2592708-1&h=2171242233&u=https%3A%2F%2Fwww.goremedical.com%2Fnews%2Fcardioform-fda-approval-for-asd-2019-06-04&a=granted+approval+by+the+U.S.+Food+and+Drug+Administration] for the treatment of atrial septal defects and is the newest addition in Gore's occluder portfolio.(*) The portfolio also includes the GORE® CARDIOFORM Septal Occluder [https://c212.net/c/link/?t=0&l=en&o=2592708-1&h=2420123105&u=https%3A%2F%2Fwww.goremedical.com%2Fproducts%2Fcardioform&a=GORE%C2%AE+CARDIOFORM+Septal+Occluder], which is indicated for ASD closure for defects up to 17 mm and received U.S. Food and Drug Administration approval in 2018 for patent foramen ovale (PFO) closure to prevent recurrent ischemic stroke. In May 2018, positive results were announced from the Gore REDUCE Clinical Study [https://c212.net/c/link/?t=0&l=en&o=2592708-1&h=1146155052&u=https%3A%2F%2Fwww.goremedical.com%2Fcardioform-pfo-closure%2Freduce-study&a=Gore+REDUCE+Clinical+Study], which demonstrated the safety and efficacy of PFO closure with a Gore device plus antiplatelet therapy compared to antiplatelet therapy alone in patients with a PFO and history of cryptogenic stroke.
*For complete indications and other important safety information for Gore commercial products referenced herein, refer to the applicable Instructions for Use (IFU).
Medical Products Division
Gore engineers medical devices that treat a range of cardiovascular and other health conditions. With more than 45 million medical devices implanted over the course of more than 40 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives. goremedical.com
W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments -- from outer space to the world's highest peaks to the inner workings of the human body. With more than 10,500 Associates and a strong, team-oriented culture, Gore generates annual revenues of $3.7 billion. gore.com
Liz Deforest Bliss Integrated Communication for Gore Medical 500 5(th) Ave #1640, New York, New York 10110, USA +1 212 584 5477 firstname.lastname@example.org [mailto:email@example.com]
Web site: https://www.goremedical.com/